GI Partners announces agreement to sell Generate Life Sciences to CooperCompanies
|Deal Type||Mergers & Acquisitions|
|Client & Transactional Partners||
Generate Life Sciences
|Our Role||Sell-Side Advisor|
GI Partners announced the signing of a definitive agreement to sell Generate Life Sciences, a leading life sciences platform that provides reproductive and newborn stem cell services to CooperCompanies (NYSE:COO) for $1.6 billion. The definitive agreement, signed in November 2021, is expected to close in December, subject to customary closing conditions.
Cain Brothers, a division of KeyBanc Capital Markets, served as financial advisor to Generate, highlighting our deep domain expertise in life sciences and our long-standing relationship with both Generate and GI Partners.
In 2018, Cain Brothers served as financial advisor to California Cryobank in its sale to GI Partners, simultaneously combining with Cord Blood Registry. It later renamed itself Generate Life Sciences. Cain Brothers also served as financial advisor to Generate on its acquisition of Cell Care Group.
Generate Life Sciences is a life sciences company helping to grow and protect families through reproductive, newborn stem cell, genetic screening, medical device and healthcare technology services. The Company serves families from preconception to post-birth. Its brands, CBR®, California Cryobank™, Donor Egg Bank USA™, NW Cryobank™, ReadyGen™, Kitazato USA™ and Donor Application™ are pioneering leaders that have helped nearly one million families.
Founded in 2001, GI Partners is a private investment firm with over 100 employees and offices in San Francisco, New York, Chicago, Greenwich and Scottsdale. The firm has raised over $29 billion in capital from leading institutional investors worldwide.
CooperCompanies operates through two business units CooperVision and CooperSurgical. CooperSurgical is committed to advancing the health of women, babies, and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. CooperCompanies has a workforce of more than 12,000 with products sold in over 100 countries.